Literature DB >> 18492491

Protein kinase CK2--a key suppressor of apoptosis.

Kashif A Ahmad1, Guixia Wang, Gretchen Unger, Joel Slaton, Khalil Ahmed.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18492491      PMCID： PMC2593134          DOI： 10.1016/j.advenzreg.2008.04.002

Source DB:  PubMed          Journal:  Adv Enzyme Regul        ISSN： 0065-2571


× No keyword cloud information.
  85 in total

Review 1.  Nuclear matrix and protein kinase CK2 signaling.

Authors:  K Ahmed
Journal:  Crit Rev Eukaryot Gene Expr       Date:  1999       Impact factor: 1.807

2.  The regulatory beta subunit of protein kinase CK2 mediates formation of tetrameric CK2 complexes.

Authors:  K C Graham; D W Litchfield
Journal:  J Biol Chem       Date:  2000-02-18       Impact factor: 5.157

3.  Protein kinase CK2: evidence for a protein kinase CK2beta subunit fraction, devoid of the catalytic CK2alpha subunit, in mouse brain and testicles.

Authors:  B Guerra; S Siemer; B Boldyreff; O G Issinger
Journal:  FEBS Lett       Date:  1999-12-03       Impact factor: 4.124

Review 4.  Subcellular localization of protein kinase CK2. A key to its function?

Authors:  M Faust; M Montenarh
Journal:  Cell Tissue Res       Date:  2000-09       Impact factor: 5.249

5.  Validation of protein kinase CK2 as oncological target.

Authors:  S Seeber; O G Issinger; T Holm; L P Kristensen; B Guerra
Journal:  Apoptosis       Date:  2005-08       Impact factor: 4.677

6.  CK2 inhibits apoptosis and changes its cellular localization following ionizing radiation.

Authors:  Kazuhiko Yamane; Timothy J Kinsella
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

7.  Protein kinase CK2 phosphorylates and upregulates Akt/PKB.

Authors:  G Di Maira; M Salvi; G Arrigoni; O Marin; S Sarno; F Brustolon; L A Pinna; M Ruzzene
Journal:  Cell Death Differ       Date:  2005-06       Impact factor: 15.828

8.  Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8.

Authors:  Soonah Shin; Yoonmi Lee; Wooseok Kim; Hyeonseok Ko; Hyeyeon Choi; Kunhong Kim
Journal:  EMBO J       Date:  2005-09-29       Impact factor: 11.598

Review 9.  Targeting CK2 for cancer therapy.

Authors:  Kashif A Ahmad; Guixia Wang; Joel Slaton; Gretchen Unger; Khalil Ahmed
Journal:  Anticancer Drugs       Date:  2005-11       Impact factor: 2.248

10.  Antisense oligonucleotides against protein kinase CK2-alpha inhibit growth of squamous cell carcinoma of the head and neck in vitro.

Authors:  R A Faust; S Tawfic; A T Davis; L A Bubash; K Ahmed
Journal:  Head Neck       Date:  2000-07       Impact factor: 3.147
View more
  90 in total

1.  Isolation of a CK2α subunit and the holoenzyme from the mussel Mytilus galloprovincialis and construction of the CK2α and CK2β cDNAs.

Authors:  Regina-Maria Kolaiti; Andrea Baier; Ryszard Szyszka; Sophia Kouyanou-Koutsoukou
Journal:  Mar Biotechnol (NY)       Date:  2010-10-05       Impact factor: 3.619

Review 2.  Emergence of protein kinase CK2 as a key target in cancer therapy.

Authors:  Janeen H Trembley; Zhong Chen; Gretchen Unger; Joel Slaton; Betsy T Kren; Carter Van Waes; Khalil Ahmed
Journal:  Biofactors       Date:  2010 May-Jun       Impact factor: 6.113

3.  CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.

Authors:  Matthew S Brown; Oumou T Diallo; Michael Hu; Reza Ehsanian; Xinping Yang; Pattatheyil Arun; Hai Lu; Vicci Korman; Gretchen Unger; Khalil Ahmed; Carter Van Waes; Zhong Chen
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

4.  Comparison of algorithms for the detection of cancer drivers at subgene resolution.

Authors:  Eduard Porta-Pardo; Atanas Kamburov; David Tamborero; Tirso Pons; Daniela Grases; Alfonso Valencia; Nuria Lopez-Bigas; Gad Getz; Adam Godzik
Journal:  Nat Methods       Date:  2017-07-17       Impact factor: 28.547

5.  Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.

Authors:  Christian Borgo; Luca Cesaro; Valentina Salizzato; Maria Ruzzene; Maria Lina Massimino; Lorenzo A Pinna; Arianna Donella-Deana
Journal:  Mol Oncol       Date:  2013-08-22       Impact factor: 6.603

6.  Impact of protein kinase CK2 on inhibitor of apoptosis proteins in prostate cancer cells.

Authors:  Guixia Wang; Kashif A Ahmad; Nathan H Harris; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2008-06-24       Impact factor: 3.396

7.  Threonine 393 of beta-catenin regulates interaction with Axin.

Authors:  Hao Wu; Karen Symes; David C Seldin; Isabel Dominguez
Journal:  J Cell Biochem       Date:  2009-09-01       Impact factor: 4.429

8.  Casein kinase 2 inhibition differentially modulates apoptotic effect of trichostatin A against epithelial ovarian carcinoma cell lines.

Authors:  Chung Soo Lee; Eun-Ra Jang; Yun Jeong Kim; Soon Chul Myung; Wonyong Kim
Journal:  Mol Cell Biochem       Date:  2009-12-18       Impact factor: 3.396

9.  In Vivo Evaluation of Combined CK2 Inhibition and Irradiation in Human WiDr Tumours.

Authors:  Felix Zwicker; Henrik Hauswald; Klaus-Josef Weber; JÜrgen Debus; Peter E Huber
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

10.  Structural and functional insights into the regulation mechanism of CK2 by IP6 and the intrinsically disordered protein Nopp140.

Authors:  Won-Kyu Lee; Sang Hyeon Son; Bong-Suk Jin; Jung-Hyun Na; Soo-Youl Kim; Kook-Han Kim; Eunice Eunkyeong Kim; Yeon Gyu Yu; Hyung Ho Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.